Mersana touts 'biggest preclinical ADC deal ever' in $1.36B biobuck deal with GSK. AstraZeneca and Daiichi Sankyo made waves with their nearly $7 billion collaboration back in spring 2019. The latest ADC tie-up to enter the biopharma fray centers around a preclinical asset, Mersana’s XMT-2056.

Mersana has enough money to bankroll operations into the first half of 2024, the biotech says. ImmunoGen, which will hear back from the FDA by Nov. 28 on its own ADC, inked a $1.7 billion biobuck deal with Eli Lilly in February.
Posted by
Tap to Copy the Short Url to This Post:
One-Stop Business News backed by Mark Cuban. Free to Use →